Trial Profile
A randomized phase 2 trial of double-blind, placebo controlled AMG 706 [motesanib] in combination with paclitaxel, or open-label bevacizumab in combination with paclitaxel, as first line therapy in women with HER2 negative locally recurrent or metastatic breast cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Motesanib (Primary) ; Bevacizumab; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 01 Aug 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Jul 2011 Additional lead trial center identified as reported by Australian New Zealand Clinical Trials Registry.
- 09 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry)